Elmar Armin Joura - Gynecology

Author Information

Elmar Armin Joura is affiliated with the Medical University of Vienna, Department of Gynecology and Obstetrics, Comprehensive Cancer Center, Vienna, Austria. He is a prominent researcher in the field of gynecology, with a specific focus on the treatment and prevention of HPV-related diseases.

Research Contributions

Elmar Armin Joura has made significant contributions to the understanding and treatment of HPV-related conditions, including vulvar intraepithelial neoplasia and cervical high-grade squamous intraepithelial lesions. His work includes clinical trials comparing topical treatments like imiquimod to surgical interventions, as well as studies on the immunogenicity and safety of HPV vaccines for different age groups. Joura's research also explores the cross-protective effects of HPV vaccines and the impact of p16ink4a positivity in invasive vulvar cancer on survival outcomes. His systematic reviews and randomized clinical trials provide critical data for the development of effective treatment protocols and preventive measures against HPV-related diseases.

Aliases

Elmar Armin Joura is also known by several aliases in academic publications, including Elmar Joura, E A Joura, E. Joura, and E. A. Joura, among others.

Publication and Citation Metrics

Metric	Value
Citation Count	9,527
h-index	41
Paper Count	171

Publications:

Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial

DOI: 10.1016/S0140-6736(22)00469-X

Year: 2022

Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.

DOI: 10.1016/j.ygyno.2022.01.033

Year: 2022

Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence.

DOI: 10.1016/j.vaccine.2020.11.076

Year: 2021

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

DOI: 10.1016/j.vaccine.2021.01.074

Year: 2021

Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.

DOI: 10.1016/j.vaccine.2021.01.060

Year: 2021

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease

DOI: 10.3390/vaccines9020083

Year: 2021

Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial

DOI: 10.1016/j.pvr.2020.100202

Year: 2020

337 Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia – PITVIN study. Baseline Results of a Randomized Clinical Trial

DOI: 10.1136/ijgc-2020-esgo.190

Year: 2020

The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study

DOI: 10.1007/s00404-020-05431-7

Year: 2020

List of Contributors

DOI: 10.1016/b978-0-12-814457-2.00030-1

Year: 2020

What are the Benefits of Genetic Counseling in Gynecology?

How Does Radioactive Iodine Work?

Are There Any Preventive Measures for BPH?

Is it possible to have a successful career and still enjoy personal time?

Why is Data Privacy Important?

What Are the Benefits of PMR in Gynecology?

How is a Diaphragm Positioned?

How Does Topical Estrogen Therapy Compare to Other Treatments?

Why Are Standards Important?

How is IVM Performed?

Partnered Content Networks

Relevant Topics